Novartis news from FiercePharma
NewsBMS: Buyer or buyout target?
Market-watchers love to speculate. Their latest topic? Bristol-Myers Squibb, which has been paring away its "non-core" businesses over the last few months. Most recently, Bristol agreed to Read more...
Profits rise at Novartis, Merck, Lilly
Good financial results from three Pharma biggies should cheer up those market-watchers who moaned their way through much of last week. Sure, a couple of the profit leaps came at least in part from Read more...
Falling dollar, falling drugmaker prices
Is the U.S. drug industry bargain-basement land right now? Analysts say that the low, low dollar means low, low prices for pharma companies. Rivals in Asia and the Eurozone could snap up drug Read more...
Vasella touts Novartis' diversification
Novartis CEO Daniel Vasella (photo) talked up his company's prospects in an interview with the Swiss weekly Sonntag, Read more...
Novartis taps new U.S. pharma chief
The musical chairs game in Novartis' top management ranks is continuing as new pharma chief Joe Jimenez revamps the ranks. The Swiss drugmaker has appointed Ludwig Hantson to top its U.S. Read more...
FDA probes Roche, Novartis meds
The transplant drug probe is widening. FDA says it's identified 16 cases of an often-fatal neurological disease among patients taking Roche's CellCept drug, used to prevent organ rejection. The Read more...
Pros use pills to boost brainpower
Fuzzy-headed today? Then pop a pill. Professionals of all kinds are doing it these days, according to a survey taken by Nature. Read more...
What did Vasella see in Alcon?
Just why would Novartis pay $11 billion for one-fourth of an eye-care company and promise another $28 Read more...
SPOTLIGHT: Novartis: No more deals, no Roche sale
Two questions raised by yesterday's Novartis-Alcon announcement. Is the Swiss drug maker in the market for Read more...
Novartis pledges $39B for Alcon
In a bid to diversify its business away from traditional pharma, Novartis has bought a 25 percent stake in Alcon and is eyeing the purchase of another 52 percent in 2010. The Swiss drugmaker paid Read more...
| Press ReleasesNew data show Menveo to be the first quadrivalent meningococcal vaccine to provide immunogenicity in infants New data show Menveo to be the first quadrivalent meningococcal vaccine to provide immunogenicity in infants Data in JAMA show Menveo may provide infants protection against four of the most common Read more... PRESS RELEASE: Novartis launches strategic initiative to improve competitiveness in a changing healthcare environmenT Novartis launches strategic initiative to improve competitiveness in a dynamically changing healthcare environment "Forward" to simplify organizational structures, accelerate and Read more... PRESS RELEASE: Novartis further strengthens biologics capabilities in expansion of MorphoSys collaboration Novartis further strengthens biologics capabilities in expansion of MorphoSys collaboration Collaboration efforts will focus on the discovery and optimization of antibodies against a significant Read more... PRESS RELEASE: Tasigna gains European approval for patients with a life-threatening form of leukemia who are resistant or intol Tasigna® gains European approval for patients with a life-threatening form of leukemia who are resistant or intolerant to existing therapies Tasigna produced response in 49% of patients with Read more... PRESS RELEASE: Antisoma Shares Slide as Novartis Corporation (NVS) Sets up Avastin Fight Antisoma Shares Slide as Novartis Corporation Sets up Avastin Fight LONDON--Nov 20, 2007 -- ASA404 phase III lung cancer trial to include broader range of patients London, UK: 20 November 2007 - Read more... |
Get more Novartis coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight